Roque DM, Siegel ER, Buza N, Bellone S, et al. Correction: Randomised phase II trial of weekly ixabepilone +/- biweekly
bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary
peritoneal cancer. Br J Cancer 2024 Mar 4. doi: 10.1038/s41416-024-02628.
PMID: 38438590